Equities Analysts Issue Forecasts for SGMO FY2028 Earnings

Key Points

• HC Wainwright cut its FY2028 EPS estimate for Sangamo to $0.27 (from $0.28) while maintaining a "Buy" rating and a $10 price target, versus a consensus FY2028 EPS of ($0.46).
• Sangamo missed its latest quarter, reporting ($0.11) EPS vs. a $0.01 consensus and revenue of $14.23M versus $40.25M, leaving the company with very negative margins and ROE.
• Analyst sentiment is mixed with an average rating of "Hold" and a $5.50 average target; the stock trades around $0.30 (market cap ≈ $101M) and is ~56.9% institutionally owned.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright reduced their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a report released on Thursday, April 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn $0.27 per share for the year, down from their previous estimate of $0.28. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2029 earnings at $0.40 EPS and FY2030 earnings at $0.57 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by ($0.12). The company had revenue of $14.23 million during the quarter, compared to the consensus estimate of $40.25 million. Sangamo Therapeutics had a negative return on equity of 1,070.18% and a negative net margin of 310.81%.

A number of other brokerages have also issued reports on SGMO. Weiss Ratings restated a "sell (e+)" rating on shares of Sangamo Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen lowered Sangamo Therapeutics to a "strong sell" rating in a report on Saturday, January 31st. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sangamo Therapeutics currently has an average rating of "Hold" and an average target price of $5.50.

Sangamo Therapeutics Price Performance

Shares of SGMO stock opened at $0.30 on Friday. The firm has a market cap of $100.98 million, a P/E ratio of -0.68 and a beta of 1.49. Sangamo Therapeutics has a 1-year low of $0.21 and a 1-year high of $0.84. The firm has a fifty day moving average of $0.38 and a two-hundred day moving average of $0.47.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. World Investment Advisors boosted its holdings in shares of Sangamo Therapeutics by 88.5% in the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 20,000 shares during the period. Cetera Investment Advisers bought a new position in Sangamo Therapeutics in the fourth quarter worth about $31,000. XTX Topco Ltd acquired a new position in Sangamo Therapeutics in the second quarter valued at approximately $41,000. Engineers Gate Manager LP boosted its stake in Sangamo Therapeutics by 101.7% in the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 44,078 shares during the period. Finally, State of Wyoming bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $47,000. 56.92% of the stock is owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company's platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.